1: Dash RP, Srinivas NR, Rais R. A review of bioanalytical quantitative methods for selected sphingosine 1-phosphate receptor modulators. Biomed Chromatogr. 2018 Jan;32(1). doi: 10.1002/bmc.4109. Epub 2017 Nov 6. PMID: 28990207.
2: Inaba SI, Yamaguchi-Goto M, Tanaka-Takanaka K, Yonesu K, Sakurai H, Kubota K, Izumi T. Enzymatic kinetics regarding reversible metabolism of CS-0777, a sphingosine 1-phosphate receptor modulator, via phosphorylation and dephosphorylation in humans. Xenobiotica. 2018 Mar;48(3):258-268. doi: 10.1080/00498254.2017.1306150. Epub 2017 Apr 3. PMID: 28287856.
3: Inaba SI, Goto M, Tanaka-Takanaka K, Tanaka H, Tomisato W, Yuita H, Doi- Komuro H, Inoue R, Oshima K, Kagari T, Shimozato T, Izumi T. Evaluation of species difference in peripheral lymphocyte reduction effect of CS-0777, a sphingosine 1-phosphate receptor modulator, based on a pharmacokinetic/pharmacodynamic model analysis. Biopharm Drug Dispos. 2016 Dec;37(9):561-573. doi: 10.1002/bdd.2048. Epub 2016 Nov 14. PMID: 27764535.
4: Inaba S, Ikeda T, Goto M, Tanaka H, Takahashi M, Iwabuchi H, Izumi T. Pharmacokinetics and disposition of CS-0777, a sphingosine 1-phosphate receptor modulator, in rats and monkeys. Xenobiotica. 2015;45(12):1063-80. doi: 10.3109/00498254.2015.1039097. Epub 2015 Jun 18. PMID: 26084376.
5: Lukas S, Patnaude L, Haxhinasto S, Slavin A, Hill-Drzewi M, Horan J, Modis LK. No differences observed among multiple clinical S1P1 receptor agonists (functional antagonists) in S1P1 receptor down-regulation and degradation. J Biomol Screen. 2014 Mar;19(3):407-16. doi: 10.1177/1087057113502234. Epub 2013 Sep 3. PMID: 24003058.
6: Sakurai H, Kubota K, Inaba S, Takanaka K, Shinagawa A. Identification of a metabolizing enzyme in human kidney by proteomic correlation profiling. Mol Cell Proteomics. 2013 Aug;12(8):2313-23. doi: 10.1074/mcp.M112.023853. Epub 2013 May 14. PMID: 23674616; PMCID: PMC3734587.
7: Moberly JB, Ford DM, Zahir H, Chen S, Mochizuki T, Truitt KE, Vollmer TL. Pharmacological effects of CS-0777, a selective sphingosine 1-phosphate receptor-1 modulator: results from a 12-week, open-label pilot study in multiple sclerosis patients. J Neuroimmunol. 2012 May 15;246(1-2):100-7. doi: 10.1016/j.jneuroim.2012.03.007. Epub 2012 Mar 31. PMID: 22465063.
8: Yonesu K, Kubota K, Tamura M, Inaba S, Honda T, Yahara C, Watanabe N, Matsuoka T, Nara F. Purification and identification of activating enzymes of CS-0777, a selective sphingosine 1-phosphate receptor 1 modulator, in erythrocytes. J Biol Chem. 2011 Jul 15;286(28):24765-75. doi: 10.1074/jbc.M110.217299. Epub 2011 May 25. PMID: 21613209; PMCID: PMC3137052.
9: Moberly JB, Rohatagi S, Zahir H, Hsu C, Noveck RJ, Truitt KE. Pharmacological modulation of peripheral T and B lymphocytes by a selective sphingosine 1-phosphate receptor-1 modulator. J Clin Pharmacol. 2012 Jul;52(7):996-1006. doi: 10.1177/0091270011408728. Epub 2011 May 12. PMID: 21566200.
10: Nishi T, Miyazaki S, Takemoto T, Suzuki K, Iio Y, Nakajima K, Ohnuki T, Kawase Y, Nara F, Inaba S, Izumi T, Yuita H, Oshima K, Doi H, Inoue R, Tomisato W, Kagari T, Shimozato T. Discovery of CS-0777: A Potent, Selective, and Orally Active S1P1 Agonist. ACS Med Chem Lett. 2011 Mar 2;2(5):368-72. doi: 10.1021/ml100301k. PMID: 24900318; PMCID: PMC4017972.
11: Rohatagi S, Zahir H, Moberly JB, Truitt KE, Inaba S, Shimozato T, Carrothers TJ. Use of an exposure-response model to aid early drug development of an oral sphingosine 1-phosphate receptor modulator. J Clin Pharmacol. 2009 Jan;49(1):50-62. doi: 10.1177/0091270008325672. Epub 2008 Oct 23. PMID: 18948412.